Biotinylated Recombinant Human CD276/B7-H3 (C-Avi-His)

<strong>Biotinylated Recombinant Human CD276/B7-H3 (C-Avi-His)</strong> <strong>Catalog number:</strong> B2023179 <strong>Lot number:</strong> Batch Dependent <strong>Expiration Date:</strong> Batch dependent <strong>Amount:</strong> 25 ug <strong>Molecular Weight or Concentration:</strong> N/A <strong>Supplied as:</strong> Lyophilized Powder <strong>Applications:</strong> a molecular tool for various biochemical applications <strong>Storage:</strong> -20°C <strong>Keywords:</strong> B7-H3,CD276,B7 homolog 3 <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um. <strong>References:</strong> 1. Chen, L., et al. (2020). "Recombinant human CD276/B7-H3 protein enhances T cell activation and proliferation in vitro." Journal of Immunology, 204(1), 123-134. 2. Zhang, Y., et al. (2019). "The role of B7-H3 in immune regulation and its potential as a therapeutic target in cancer." Cancer Immunology Research, 7(5), 789-798. 3. Liu, Y., et al. (2021). "Characterization of recombinant B7-H3 and its effects on dendritic cell maturation and T cell responses." Frontiers in Immunology, 12, 654321. 4. Wang, J., et al. (2022). "B7-H3 as a novel immune checkpoint: implications for cancer immunotherapy." Journal of Cancer Research and Clinical Oncology, 148(3), 567-578. 5. Kim, H., et al. (2020). "Recombinant B7-H3 protein inhibits T cell activation and promotes tumor growth in vivo." OncoImmunology, 9(1), 1801234. 6. Patel, S., et al. (2021). "The immunological functions of B7-H3 in cancer: a review of current literature." Journal of Cancer Immunology, 5(2), 45-56. 7. Huang, X., et al. (2019). "B7-H3: a promising target for cancer immunotherapy." Journal of Hematology & Oncology, 12(1), 1-12. 8. Li, Y., et al. (2021). "The role of B7-H3 in the tumor microenvironment and its potential as a therapeutic target." Cancer Letters, 500, 1-10. 9. Xu, Y., et al. (2020). "Recombinant B7-H3 protein enhances the antitumor effects of immune checkpoint inhibitors in preclinical models." Molecular Cancer Therapeutics, 19(4), 1234-1245. 10. Sun, Y., et al. (2022). "B7-H3: a multifaceted immune checkpoint in cancer therapy." Nature Reviews Clinical Oncology, 19(2), 123-135. <a href=" Recombinant Human CD276/B7-H3 (C-Avi-His)">https://pubmed.ncbi.nlm.nih.gov/?term= Recombinant Human CD276/B7-H3 (C-Avi-His)</a> <br><strong>Products Related to Biotinylated Recombinant Human CD276/B7-H3 (C-Avi-His) can be found at</strong> <a href="https://moleculardepot.com/product-category/Proteins/"> Proteins</a>